Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Morisco, Filomena ^a   Guarino, Maria ^a   La Bella, Serena ^a   Di Costanzo, Luisa ^a   Caporaso, Nicola ^a   Ayala, Fabio ^a   Balato, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biological drugs; HBV reactivation; HCV infection; Immunosuppressive therapy; Lamivudine; Psoriasis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; USTEKINUMAB; HEPATITIS B ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION; ADOLESCENT; BLOOD; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84964314209     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-014-0214-x     Document Type: Article

References (38)

1. Schon MP, Boehncke WH: Psoriasis. N Engl J Med 2005, 352(18):1899-1912.
2. Naldi L: Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004, 3(2):121-128.
3. Kivelevitch DN, Hebeler KR, Patel M, Menter A: Emerging topical treatments for psoriasis. Expert Opin Emerg Drugs 2013, 18(4):523-532.
4. Balato N, Di Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M: Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol 2012, 2012:747204.
5. Daudn E, Castaeda S, Surez C, Garca-Campayo J, Blasco AJ, Aguilar MD, Ferrndiz C, Puig L, Snchez-Carazo JL, Working Group on Comorbidity in Psoriasis: Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013, 27(11):1387-1404. doi:10.1111/jdv.12024.
6. Picardi M, De Rosa G, Selleri C, Pane F, Rotoli B, Muretto P: Clinical relevance of intrahepatic hepatitis B virus DNA in HBsAg-negative HBcAb-positive patients undergoing hematopoietic stem cell transplantation for haematological malignancies. Transplantation 2006, 82(1):141-142.
7. Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F: Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014, 20(13):3516-3524.
8. Liang R, Lau G, Kwong Y: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999, 17(1):394-398.
9. Persico M, De Marino F, Di Giacomo Russo G, Morante A, Rotoli B, Torella R, De Renzo A: Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002, 99(2):724-725.
10. Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344(1):68-69.
11. Francisci D, Falcinelli F, Schiaroli E, Capponi M, Belfiori B, Flenghi L, Baldelli F: Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010, 38(1):58-61.
12. Yagci M, Ozkurt Z, Yegin Z, Aki Z, Sucak GT, Haznedar R: Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies. Hematology 2010, 15(4):240-244.
13. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, Mizokami M: Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011, 83(3):412-418.
14. Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkins lymphomas: high prevalence of acquired viral genomic mutations. J Haematol 2003, 88(11):1296-1303.
15. Huang Y, Lin H, Lee S: Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc 2012, 75(8):359-362.
16. Lee I, Huang Y, Chu C, Lee PC, Lin HC, Lee SD: Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010, 73(3):156-160.
17. Hui C, Cheung W, Zhang H, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131(1):59-68.
18. Wu J, Huang Y, Lee P, Lin HC, Lee SD: Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 2009, 43(5):496-498.
19. Koskinas J, Tampaki M, Doumba PP, Rallis E: Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surfaceantigen- negative anti-HBs-positive patient. Br J Dermatol 2013, 168(3):679-680.
20. Fotiadou C, Lazaridou E, Ioannides D: Safety of anti-tumour necrosis factor- agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. JEADV 2011, 25(4):471-474.
21. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R: Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995, 108(5):1453-1463.
22. Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA: Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011, 25(2):285-289.
23. Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T: Tumour necrosis factor-a antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011, 164(3):645-647.
24. Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrn M, Garca-Bustinduy M, Romero-MatA, Pedragosa R, Garca-Diez A, Daudn E: Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013, 168(3):609-616.
25. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF: The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C. Br J Dermatol 2013, 169(6):1295-1303.
26. Navarro R, Concha-Garzon MJ, Castano C, Casal C, Guiu A, Daudn E: Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Intern J Dermatol 2014, 65:1241-1245.
27. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezz M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R: Long-term safety of anti-TNF-a in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014, 33(2):273-276.
28. Navarro R, Concha-Garzn MJ, Castao C, Casal C, Guiu A, Daudn E. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol. 2014 Feb 14. doi:10.1111/ijd.12313. [Epub ahead of print]
29. European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
30. European Association for the Study of the Liver: EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60(2):392-420.
31. Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014, 14:31.
32. Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, Guarino M, Biancone L, Caruso A, D'Inca R, Marmo R, Orlando A, Riegler G, Donnarumma L, Camera S, Zorzi F, Renna S, Bove V, Tontini G, Vecchi M, Caporaso N: Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013, 20(3):200-208.
33. Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P, Oliviero F, Campana C, Punzi L: Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol 2012, 41(6):490-491.
34. Nez-Rodrguez MH, Santamara-Martnez A, Mata-Romn L, Caro-Patn A: Reactivation of hepatitis B treated with adefovir after infliximab administration. Med Clin (Barc) 2006, 126(14):558-559.
35. Prez-Alvarez R, Daz-Lagares C, Ga rca-Hernndez F, Lopez-Roses L, Brito-Zern P, Prez-de-Lis M, Retamozo S, Bov A, Bosch X, Sanchez- Tapias JM, Forns X, Ramos-Casals M, BIOGEAS Study Group: Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011, 90(6):359-371.
36. Dernis E, Lavie F, Salliot C, Flipo RM, Saraux A, Maillefert JF, Paul C, Goupille P, Cantagrel A, Claudepierre P, Gaudin P, Tebib J, Wendling D, Schaeverbeke T, Le Lot X, Combe B: Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion. Joint Bone Spine 2009, 76(5):524-531.
37. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, British Association of Dermatologists: British association of dermatologists guidelines for use of biological interventions in psoriasis 2005 Br J Dermatol 2005, 153(3):486-497.
38. Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, Komine M, Etoh T, Igarashi A, Torii H, Asahina A, Nemoto O, Nakagawa H, Biologics Review Committee of the Japanese Dermatological Association: Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013, 40(9):683-695.